AnaCardio receives patent grant in Europe for AC01

Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced […]

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

February 25, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first patient has been dosed in the phase 2a part of the GOAL-HF1 study evaluating AC01 in patients with HFrEF. AC01 is a novel, selective oral ghrelin receptor (GHSR1a) agonist, […]

AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure

Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) January 9, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced the completion of a USD 19 million (SEK 205 million) Series A extension […]

AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update

Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure, today announced that the clinical conduct of the first part of its GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) has been completed. Part A of GOAL-HF1 is a randomized, […]

Michael Grissinger appointed as new Chairman of AnaCardio

Stockholm, Sweden, June 3, 2024  AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board. Michael has had a long and successful career in the pharmaceutical industry, leading large value business  development transactions […]

AnaCardio appoints Elin Rosendahl as CDO

Stockholm, Sweden, April 3, 2024 AnaCardio AB announces today the appointment of Elin Rosendahl, MSc as Chief Development Officer  (CDO). Elin has more than 20 years of experience in managing global biopharmaceutical development  programs and leading global cross-functional teams in both small and large pharma companies, and joins  AnaCardio from her previous role as Vice […]

AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study

Stockholm, Sweden, August 17, 2023  AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel  contractile agents to treat patients with heart failure, today announced that the U.S. Food and  Drug Administration (FDA) has granted the company’s Investigational New Drug (IND)  application for the investigational drug AC01. The approval enables expansion of the clinical  development […]

AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Solna, Sweden and Lugano, Switzerland, April 13, 2023 AnaCardio, a Swedish clinical-stage  biopharmaceutical company focussed on developing novel contractile agents with a unique mode of-action based on the ghrelin signaling pathway, today announced that the first patient has been  successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced  ejection […]